Being a $100 million spin-out of Illumina will surely get you a foot in the door at any life science VC firm. Raising a further $900 million (and counting) — that requires something a little extra.
So who is Grail, the cancer diagnostics company that last week raised what could be the largest-ever equity financing round in biopharma history? How has it shaped a field of diagnostics into a billion-dollar venture in just over a year?
While the company hasn’t been particularly forthcoming with information, a lot can be gleaned from CEO Jeff Huber’s presentation at the Future of Genomic Medicine conference held in San Diego last week.
